{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:39:51Z","timestamp":1789544391672,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hodgkin\u2019s lymphoma (HL) is one of the most curable malignancies with a 5-year survival of over 80%. Most published literature from low-middle income countries comes from single institute experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>The OncoCollect Lymphoma group registry was set up in 2017 and has 9 major participating sites across India. Data of newly diagnosed classical HL (CHL) patients, treated between 2011 and 2017, were collected using OncoCollect software. The clinical features, subtypes, prognostic stratification, treatment patterns, response to first-line treatment, and 5-year outcomes were analyzed. All statistical analysis was done using Microsoft R Open statistical software linked to OncoCollect software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 939 newly diagnosed CHL patients with a median age of 38 (range, 18\u201399) years at presentation. The male-to-female ratio was 2.07:1. Histological subtypes included mixed cellularity, CHL (MC, CHL), nodular sclerosis, CHL (NS, CHL), lymphocyte-rich, CHL (LR, CHL), and lymphocyte-depleted, CHL (LD, CHL), in 60.60%, 26.94%, 9.80%, and 2.66%, respectively. At presentation, 50.43% had B symptoms and 53.35% had advanced disease. 29.71% of advanced-stage patients had high Hodgkin IPI score. 79% and 21% of patients received 1st-line treatment with chemotherapy alone or combined modality treatment with chemotherapy and radiotherapy. The most common first-line chemotherapy was ABVD-based regimen (94.68%). The overall response rate was 93.48%. Complete response rates among early-stage favorable and unfavorable risk groups were 92.73% and 86.79%, and those among advanced-stage low- and high-risk groups were 76.64% and 69.78%, respectively. The median relapse-free follow-up duration was 51 months (IQR 22\u201369). A significant difference was found in 5-year EFS between the early- and advanced-stage disease 83.53% and 73.55% (p = 0.00087), respectively. Similarly, significant difference was found in EFS among early-stage patients treated with a combination of 4-cycle chemotherapy and radiotherapy vs. chemotherapy alone 88.57% and 66.33% (p = 0.0042), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large cohort from India, survival of patients with HL was comparable to the developed world. With a median follow-up of 51 months, the 5-year EFS and OS of all patients were 78.24% and 83.63%, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2021.799948","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T07:12:33Z","timestamp":1644563553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India"],"prefix":"10.3389","volume":"11","author":[{"given":"Dinesh","family":"Bhurani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Rajappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparna Ajit","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Reddy","family":"Boya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganapathi S.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Seshachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"B1","first-page":"5","article-title":"A Review of Hodgkin\u2019s Disease at the Cancer Institute, Madras","volume":"8","author":"Shanta","year":"1982","journal-title":"Clin Oncol"},{"key":"B2","article-title":"Hodgkin\u2019s Disease: A Retrospective Analysis of 15 Years Experience at a Large Referral Center","volume":"11","author":"Chandi","year":"1998","journal-title":"Natl Med J Ind"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation Radiation After Complete Remission in Hodgkin\u2019s Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine and Dacarbazine Chemotherapy: Is There a Need","volume":"22","author":"Laskar","year":"2004","journal-title":"L Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1262-8","article-title":"Hodgkin Lymphoma- Long Term Outcomes: An Experience From a Tertiary Care Center in North India","volume":"90","author":"Ganessan","year":"2011","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.171550","article-title":"Clinical Profile and Outcomes of Adult Hodgkin Lymphoma. Experience From a Tertiary Care Institute","volume":"36","author":"Maddi","year":"2015","journal-title":"In J Med Pediatr Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jcrt.JCRT_465_17","article-title":"Combined Modality Treatment: Outcome in Patients With Hodgkin\u2019s Lymphoma","volume":"16","author":"Yadav","year":"2020","journal-title":"J Cancer Res Thera"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.00179","article-title":"Does Interim PET Scan After 2 Cycles of ABVD Predict Outcomes in Hodgkin Lymphoma? Real World Evidence","volume":"5","author":"Seshachalan","year":"2019","journal-title":"J Glob Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28049","article-title":"Hodgkin\u2019s Lymphoma Mortality in the Americas, 1997-2008: Achievements and Persistent Inadequacies","volume":"133","author":"Chatenoud","year":"2013","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.523","article-title":"Treatment Outcomes for Hodgkin Lymphoma: First Report From the Brazilian Prospective Registry","volume":"36","author":"Biasoli","year":"2018","journal-title":"Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The Conundrum of Hodgkin Lymphoma Nodes: To be or Not to be Included in the Involved Node Radiation Fields. The EORTC-GELA Lymphoma Group Guidelines","volume":"88","author":"Girinsky","year":"2008","journal-title":"Radiother Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0013","article-title":"NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018","volume":"16","author":"Hoppe","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00467.x","article-title":"The EORTC Strategy in the Treatment of Hodgkin\u2019s Lymphoma","author":"Eghbali","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104","article-title":"A Prognostic Score for Advanced Hodgkin\u2019s Disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"JCO"},{"key":"B15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved Survival Time Trends in Hodgkin\u2019s Lymphoma","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2017.08.001","article-title":"High Frequency of Primary Refractory Disease and Low Progression-Free Survival Rate of Hodgkin\u2019s Lymphoma: A Decade of Experience in a Latin American Center","volume":"39","author":"Jaime-P\u00e9rez","year":"2017","journal-title":"Rev Bras Hematol e Hemoter"},{"key":"B17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.5306\/wjco.v12.i9.800","article-title":"Long-Term Results of the Treatment of Hodgkin\u2019s Lymphoma in a Resource-Constrained Setting: Real-World Data From a Single Center","volume":"12","author":"S\u00e1nchez-Valledor","year":"2021","journal-title":"World J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820715)50:2<353::AID-CNCR2820500232>3.0.CO;2-#","article-title":"Hodgkin\u2019s Disease in Western India: Review of 1082 Cases","volume":"50","author":"Talvalkar","year":"1982","journal-title":"Cancer"},{"key":"B19","unstructured":"GenevaWorld Health OrganizationGlobal Tuberculosis Report 20202020"},{"key":"B20","unstructured":"New DelhiNational Health MissionIndia TB Report 20212021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4103\/ijpvm.IJPVM_492_17","article-title":"Tuberculosis in India: Road to Elimination","volume":"10","author":"Singh","year":"2019","journal-title":"Int J Prev Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841001)54:7<1276::AID-CNCR2820540708>3.0.CO;2-E","article-title":"Management of Hodgkin\u2019s Disease in Western India","volume":"54","author":"Dinshaw","year":"1984","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.08.036","article-title":"Hodgkin\u2019s Lymphoma in Indian Children: Prevalence and Significance of Epstein-Barr Virus Detection in Hodgkin\u2019s and Reed-Sternberg Cells","volume":"43","author":"Dinand","year":"2007","journal-title":"Eur J Cancer"},{"key":"B24","article-title":"Hodgkin\u2019s Disease (Retrospective Study of 119 Cases)","volume":"10","author":"Vashisht","year":"1973","journal-title":"Indian J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of Advanced Hodgkin\u2019s Disease With MOPP, ABVD, or MOPP Alternating With ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/0031302031000123164","article-title":"Hodgkin\u2019s Lymphoma: Immunohistochemical Features and its Association With EBV LMP-1. Experience From a South Indian Hospital","volume":"35","author":"Karnik","year":"2003","journal-title":"Pathology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16289","article-title":"Impact of Imaging Modality on Clinical Outcome in Hodgkin Lymphoma in a Resource Constraint Setting","volume":"188","author":"Korula","year":"2020","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin\u2019s Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064601","article-title":"EORTC-GELA H8 Trial. Chemotherapy Plus Involved-Field Radiation in Early-Stage Hodgkin\u2019s Disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21995","article-title":"Hodgkin Disease Survival in Europe and the U.S.: Prognostic Significance of Morphologic Groups","volume":"107","author":"Allemani","year":"2006","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802663205","article-title":"How Much Does it Cost to Treat Children With Hodgkin Lymphoma in Africa","volume":"50","author":"Stefan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv077","article-title":"Phase II Study of Interim PET-CT-Guided Response-Adapted Therapy in Advanced Hodgkin\u2019s Lymphoma","volume":"26","author":"Ganesan","year":"2015","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: Risk-Adapted Treatment of Nonbulky Early-Stage Hodgkin Lymphoma Based on Interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced Treatment Intensity in Patients With Early-Stage Hodgkin\u2019s Lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/0022-3859.150446","article-title":"Treatment Resultsin Advanced Stage Hodgkins Lymphoma: A Retrospective Study","volume":"61","author":"Jain","year":"2015","journal-title":"J\u00a0Postgrad Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0285","article-title":"Survival Expectations of Patients Diagnosed With Hodgkin\u2019s Lymphoma in 2006-2010","volume":"14","author":"Brenner","year":"2009","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing Improvement in Long-Term Survival of Patients With Hodgkin Disease at All Ages and Recent Catch-Up of Older Patients","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70246-2","article-title":"Recent Cancer Survival in Europe: A 2000-02 Period Analysis of EUROCARE-4 Data","volume":"8","author":"Verdecchia","year":"2007","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2021.1976912","article-title":"Brentuximab Vedotin and Bendamustine: An Effective Salvage Therapy for Relapsed or Refractory Hodgkin Lymphoma Patients","volume":"4","author":"Uncu Ulu","year":"2021","journal-title":"J Chemother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2019.05.005","article-title":"A Targeted Salvage Therapy With Brentuximab Vedotin in Heavily Treated Refractory or Relapsed Pediatric Hodgkin Lymphoma Patients Before and After Stem Cell Transplantation","volume":"61","author":"Ta\u00e7y\u0131ld\u0131z","year":"2019","journal-title":"Turk J Pediatr"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1702178","article-title":"Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma Who Relapsed After Salvage Autologous Stem Cell Transplantation and\/or Brentuximab Vedotin Therapy: KEYNOTE-087 Subgroup Analysis","volume":"61","author":"Zinzani","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.799948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T07:12:41Z","timestamp":1644563561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.799948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":41,"alternative-id":["10.3389\/fonc.2021.799948"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.799948","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"article-number":"799948"}}